BRAIN Biotech (0RFI) Stock Overview
Provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
0RFI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BRAIN Biotech AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.09 |
| 52 Week High | €4.47 |
| 52 Week Low | €1.81 |
| Beta | 0.77 |
| 1 Month Change | 35.53% |
| 3 Month Change | 38.57% |
| 1 Year Change | 4.04% |
| 3 Year Change | -45.41% |
| 5 Year Change | -57.22% |
| Change since IPO | -67.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RFI | GB Chemicals | GB Market | |
|---|---|---|---|
| 7D | 2.7% | 0.7% | 0.2% |
| 1Y | 4.0% | -6.4% | 15.4% |
Return vs Industry: 0RFI exceeded the UK Chemicals industry which returned -4.5% over the past year.
Return vs Market: 0RFI underperformed the UK Market which returned 15.2% over the past year.
Price Volatility
| 0RFI volatility | |
|---|---|
| 0RFI Average Weekly Movement | 12.1% |
| Chemicals Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.9% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RFI's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0RFI's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 300 | Aryan Moelker | www.brain-biotech.com |
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. It operates through three segments: BioProducts, BioScience, and BioIncubator. The company offers enzymes, biocatalysts, microorganisms, and other bioactive natural compounds to produce foodstuffs and animal feed, cosmetics, and medical products, as well as for industrial applications in chemical companies, waste and hazardous materials disposal, and energy and raw materials production.
BRAIN Biotech AG Fundamentals Summary
| 0RFI fundamental statistics | |
|---|---|
| Market cap | €68.38m |
| Earnings (TTM) | -€11.69m |
| Revenue (TTM) | €53.61m |
Is 0RFI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RFI income statement (TTM) | |
|---|---|
| Revenue | €53.61m |
| Cost of Revenue | €23.63m |
| Gross Profit | €29.99m |
| Other Expenses | €41.68m |
| Earnings | -€11.69m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Jan 14, 2026
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 55.93% |
| Net Profit Margin | -21.81% |
| Debt/Equity Ratio | 0% |
How did 0RFI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/03 08:03 |
| End of Day Share Price | 2025/12/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BRAIN Biotech AG is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gerhard Schwarz | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Thomas Meyer | Baader Helvea Equity Research |